
Hims & Hers Health is rated a strong buy with an implied share price of $23.8, suggesting about 20% upside. The company expects revenue to reach at least $650 million in 2026 and $1 billion in 2027, driven mainly by international expansion and product growth. However, it faces short-term challenges including a drop in Q3 gross margin to 57% and a sequential decline of 103,000 subscribers. Expanded offerings in weight loss and peptides support future growth, but risks include privacy concerns and ongoing subscriber losses.
Hims & Hers shares are trading at $18.64 on Pluang as of Nov 17, 2026 03:31 WIB, down 5.52% in one day and well below their 52-week high of $40.02. This places the current price closer to the 52-week low of $14.52, reflecting recent challenges despite the company's optimistic growth outlook. The market shows a selling bias with 67% of order activity as sells compared to 33% buys, indicating cautious sentiment among investors.